Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Samsung Bioepis launches Remicade biosmiliar

South Korea’s Samsung Bioepis started U.S sales of its copy of Johnson & Johnson’s blockbuster rheumatoid arthritis drug Remicade.

Read More »

Lilly and Nektar Therapeutics Announce Alliance

Eli Lilly and Nektar Therapeutics announced a strategic collaboration to co-develop NKTR-358, a novel immunological therapy discovered by Nektar.

Read More »

U.S. Food and Drug Administration Expands Approval of Yervoy to Include Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration expanded the indication for Yervoy (ipilimumab) injection for intravenous use to now include the treatment of unresectable or metastatic melanoma in pediatric patients 12 years of age and older.

Read More »

Mitsubishi Tanabe Coughs Up $1.1 Billion Cash for Parkinson’s Biotech NeuroDerm

Shares of Israel-based NeuroDerm Limited soared more than 16 percent in premarket trading after the company announced it was being snapped up by Tokyo-based Mitsubishi Tanabe Corporation.

Read More »

Republicans’ push to roll back Obamacare faces crucial test

A seven-year Republican effort to repeal and replace Obamacare faces a major test in the U.S. Senate, where lawmakers will decide whether to move forward and vote on a bill whose details and prospects are uncertain.

Read More »

Discovery Worldwide Names Rico Ricketson as Head of Client Services

Discovery Worldwide, a healthcare communications agency that combines the power of science, storytelling and innovative delivery to move health forward, announced the appointment of Rico Ricketson as Head of Client Services.

Read More »

Roche’s Tecentriq receives positive opinion from EU medicines agency

A European Medicines Agency (EMA) panel recommended Roche’s immunotherapy Tecentriq as a treatment for advanced bladder and lung cancer, setting the stage for European Commission approval during 2017.

Read More »

AbbVie Receives CHMP Positive Opinion for Humira

The EMA’s CHMP granted a positive opinion for Humira (adalimumab) for the treatment of chronic non-infectious anterior uveitis in pediatric patients from 2 years of age.

Read More »

CSL Behring Receives Orphan-Drug Exclusivity for Haegarda

FDA granted orphan-drug exclusivity for Haegarda for the prevention of hereditary angioedema attacks.

Read More »

Corning, Merck & Co. and Pfizer to Invest $4 Billion and Create 4,000 New Jobs in the U.S.

Corning announced at President Trump’s “Made in America” event that the company planned to create 1,000 new high-tech jobs in the U.S.

Read More »

AstraZeneca CEO Breaks Silence on Teva Rumors, Urges Staff to Remain Focused in Leaked Memo

July 21, 2017 By Alex Keown, Breaking News Staff LONDON – After a period of uncertainty, AstraZeneca (AZN) Chief Executive Officer Pascal Soriot finally broke his silence to squelch rumors he was departing the company and urged his employees to remain focused on the company’s goals. In an internal memo sent earlier this week […]

Read More »

Endo International Slashes 875 Jobs and Will Shutter Alabama Facilities

July 21, 2017 By Alex Keown, Breaking News Staff DUBLIN – Less than one month after Endo International (ENDP) agreed to pull its opioid pain medication, the reformulated Opana ER, from the market, the company announced it was shuttering a manufacturing facility in Alabama and terminating hundreds of employees. Endo said the move follows […]

Read More »

Pfizer, Merck KGaA skin cancer drug gets EMA nod for approval

(Reuters) – European regulators on Friday recommended approving Pfizer Inc and Merck KGaA’s immuno-oncology drug Bavencio to treat a rare type of skin cancer called Merkel cell carcinoma. In May, Bavencio was approved by the U.S. Food and Drug Administration to treat bladder cancer and in March to treat Merkel cell carcinoma. ( Bavencio, known […]

Read More »

EU medicines agency recommends approval of Novartis leukemia drug Rydapt

ZURICH (Reuters) – A European Medicines Agency (EMA) panel recommended on Friday approval of a new Novartis drug to be used against a tough-to-cure form of blood cancer as the Swiss drugmaker makes headway on refreshing its oncology portfolio. The EMA’s Committee for Medicinal Products for Human Use (CHMP) backed Rydapt against acute myeloid leukemia […]

Read More »

Living healthily, learning more could cut dementia cases by a third

Learning new things, eating and drinking well, not smoking and limiting hearing loss and loneliness could prevent a third of dementia cases, health experts said.

Read More »

Klick Health Expands Behavioral Science Team

Klick Health announced it is expanding its Behavioral Science team as part of its extensive lineup of in-house, full-service healthcare marketing and commercialization capabilities.

Read More »

MAHF to hold its first Midwest seminar in September

The Medical Advertising Hall of Fame will be holding its first Midwest event on Sept. 21, 2017, at the offices of the Sandbox Agency in Chicago.

Read More »

Ironwood’s Potential Blockbuster Drug Meets Main Goals in Mid-Stage Trial

Ironwood Pharmaceuticals touted its Phase IIb drug candidate IW-3718 in adult patients with uncontrolled gastroesophageal reflux disease (GERD), but investors seem wary as share prices were down more than 7 percent.

Read More »

Kite Pharma Touts Remissions Up to 56+ Months in Non-Hodgkin Lymphoma Patients on CAR T-Cell Therapy

Kite Pharma noted the publication of data related to its anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for aggressive non-Hodgkin’s lymphoma, including diffuse large B-cell lymphoma.

Read More »

Hundreds of Jobs to Go as GlaxoSmithKline Shutters Manufacturing Site

GlaxoSmithKline is selling off the UK part of its Horlicks malted milk beverage company as well as its MaxiNutrition sports drink brand. Also as part of a restructuring, GSK halted plans for a biopharmaceutical manufacturing facility in Cumbria, UK, which was expected to cost 350 million pounds.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom